Royalty Pharma PLC $RPRX Shares Bought by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. grew its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 55.1% during the 2nd quarter, Holdings Channel.com reports. The firm owned 34,263 shares of the biopharmaceutical company’s stock after purchasing an additional 12,171 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Royalty Pharma were worth $1,234,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of RPRX. Victory Capital Management Inc. boosted its stake in shares of Royalty Pharma by 270.4% during the 1st quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock worth $112,788,000 after purchasing an additional 2,644,923 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Royalty Pharma by 2,543.7% during the 1st quarter. Los Angeles Capital Management LLC now owns 1,081,128 shares of the biopharmaceutical company’s stock worth $33,656,000 after purchasing an additional 1,040,234 shares during the last quarter. Jupiter Asset Management Ltd. boosted its stake in shares of Royalty Pharma by 462.1% during the 1st quarter. Jupiter Asset Management Ltd. now owns 1,090,591 shares of the biopharmaceutical company’s stock worth $33,950,000 after purchasing an additional 896,555 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Royalty Pharma during the 1st quarter worth about $27,749,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Royalty Pharma by 37.0% during the 1st quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company’s stock worth $80,381,000 after acquiring an additional 704,414 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

RPRX has been the topic of several recent analyst reports. Morgan Stanley cut their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Citigroup increased their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. The Goldman Sachs Group initiated coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. Weiss Ratings upgraded shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $46.00.

Royalty Pharma Trading Down 1.7%

NASDAQ RPRX opened at $36.84 on Thursday. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $38.00. The company’s 50 day moving average price is $36.10 and its 200 day moving average price is $34.91. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. The firm has a market capitalization of $21.48 billion, a price-to-earnings ratio of 21.29, a PEG ratio of 2.06 and a beta of 0.60.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million for the quarter, compared to analyst estimates of $750.06 million. On average, sell-side analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $0.22 dividend. The ex-dividend date is Friday, November 14th. This represents a $0.88 annualized dividend and a yield of 2.4%. Royalty Pharma’s dividend payout ratio (DPR) is presently 50.87%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.